Validating a Potential Prognostic 7-lncRNA Signature for Predicting Survival in Multiple Myeloma

Several long non-coding RNAs (lncRNAs) can be used to predict multiple myeloma (MM) prognosis, according to a study published in BioMed Research International. 

In this study, researchers used a seven-lncRNA signature to identify and develop a risk score system for MM prognosis. The system was designed to stratify patients into high- and low-risk groups based on survival rates. The researchers used Cox regression analysis, Kaplan-Meier, and receiver operating characteristic analysis to validate the prediction model. Single sample gene set enrichment and Kyoto Encyclopedia of Genes and Genomes analysis were used to predict the function of lncRNA, the researchers noted.

According to the results, functional enrichment analysis indicated that seven prognostic lncRNAs may be involved in the formation of tumors in MM through cancer-related pathways and biological processes. The researchers noted that the results of the immune score showed that IF_I was negatively correlated with the risk score. Moreover, compared with the published gene signature, the 7-lncRNA model demonstrated a C-index.

“In summary, our data provide evidence that seven lncRNAs could be used as independent biomarkers to predict the prognosis of myeloma, which also indicated that these 7-lncRNAs may be involved in the progression of myeloma,” the researchers concluded.